Lixisenatide in the treatment of Type 2 diabetes

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

M Donsmark and LB Knudsen are both full-time employees of Novo Nordisk A/S, which markets liraglutide for the treatment of diabetes. The authors hold minor stock portions as part of an employee offering program. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

The authors thank Watermeadow Medical, funded by Novo Nordisk A/S, for writing assistance.

Notes